aholt@cooley.com
Austin Holt focuses on the representation of private and public companies with respect to executive compensation and employee benefits matters.
Download full bio
Sweetgreen – $418.6 Million IPO
PatientPop to Combine With Kareo to Form Tebra
Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion
Lyell Immunopharma – $425 Million IPO
Cooley Guides LegalZoom on IPO, Concurrent Private Placement
View all
Compensation & Benefits
Georgetown University Law CenterLLM, Taxationwith distinction, 2009
Chapman University Dale E. Fowler School of LawJD, cum laude, 2008
Chapman UniversityMBA, 2008
University of California, RiversideBA, Philosophy2004
California
Sweetgreen – $418.6 Million IPO December 6, 2021
PatientPop to Combine With Kareo to Form Tebra November 11, 2021
Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion August 5, 2021
+1 310 883 6449
Locations